









Markets
/
Stocks
/
nasdaq-cgon
/

CG Oncology Inc

CGON

50.360USD

+1.160+2.36%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.94BMarket Cap

LossP/E TTM



CG Oncology Inc

50.360

+1.160+2.36%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CG Oncology Inc

Currency: USD Updated: 2026-02-06

Key Insights

CG Oncology Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 36 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 81.00.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CG Oncology Inc's Score

Industry at a Glance

Industry Ranking

36 / 392

Overall Ranking

137 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

CG Oncology Inc Highlights

StrengthsRisks

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 496.34% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.14M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.14M.

Fairly Valued

The company’s latest PE is -24.65, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 88.33M shares, increasing 0.51% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 1.52M shares of this stock.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

81.000

Target Price

+64.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of CG Oncology Inc is 7.14, ranking 150 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.67M, representing a year-over-year increase of 3774.42%, while its net profit experienced a year-over-year increase of 114.69%.

Score

Industry at a Glance

Previous score

7.14

Change



Financials

7.20

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.94

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.08

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.47

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

CG Oncology Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of CG Oncology Inc is 7.06, ranking 179 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -24.65, which is -60.64% below the recent high of -9.70 and -82.07% above the recent low of -44.88.

Score

Industry at a Glance

Previous score

7.06

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 36/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of CG Oncology Inc is 8.40, ranking 124 out of 392 in the Biotechnology & Medical Research industry. The average price target is 68.50, with a high of 100.00 and a low of 55.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

81.000

Target Price

+55.83%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

CG Oncology Inc

CGON

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of CG Oncology Inc is 7.19, ranking 93 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 57.74 and the support level at 43.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.27

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-1.816

Neutral

RSI(14)

50.147

Neutral

STOCH(KDJ)(9,3,3)

21.008

Neutral

ATR(14)

2.732

Low Volatility

CCI(14)

-143.533

Sell

Williams %R

80.256

Oversold

TRIX(12,20)

0.708

Sell

StochRSI(14)

21.144

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

51.688

Sell

MA10

52.615

Sell

MA20

53.572

Sell

MA50

46.219

Buy

MA100

43.394

Buy

MA200

34.959

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of CG Oncology Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 117.40%, representing a quarter-over-quarter decrease of 5.22%. The largest institutional shareholder is The Vanguard, holding a total of 6.53M shares, representing 8.10% of shares outstanding, with 5.90% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

6.57M

+11.37%

Decheng Capital LLC

6.37M

Wellington Management Company, LLP

5.51M

+190.32%

Longitude Capital Management Co., LLC

4.66M

BlackRock Institutional Trust Company, N.A.

3.95M

+3.46%

Fidelity Management & Research Company LLC

3.69M

-0.97%

TCG Crossover Management, LLC

3.67M

ORI Capital Limited

3.58M

-0.29%

Braidwell LP

3.28M

Foresite Capital Management, LLC

3.23M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CG Oncology Inc is 5.83, ranking 36 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.